Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 10mg
  • 25mg
  • 50mg

capsule

  • 25mg
  • 50mg
  • 100mg

syrup/oral suspension

  • 10mg/5mL

injectable solution

  • 25mg/mL
  • 50mg/mL

Anxiety

Symptomatic relief of anxiety associated with psychoneurosis and as adjunct in organic disease states

50-100 mg PO divided q6hr or 50-100 mg IM divided q4-6hr

Dosing considerations

  • Continuation of therapy for >4 months has not been studied; reassess need for therapy periodically

Pruritus

Management of pruritus due to chronic urticaria, contact dermatoses, and histamine-mediated pruritus

25 mg PO/IM divided q6-8hr

Preoperative Sedation

50-100 mg PO or 25-100 mg IM

Dosing considerations

  • If treatment is initiated IM, subsequent doses may be administered PO

Nausea & Vomiting (Off-label)

25-100 mg IM

Dosing Modifications

Renal Impairment

  • >50 mL/min: Dose adjustment not necessary
  • ≤50 mL/min: Administer 50% normal dose

Hepatic Impairment

  • Change dosing interval to q24hr in patients with biliary cirrhosis

Dosage Forms & Strengths

tablet

  • 10mg
  • 25mg
  • 50mg

capsule

  • 25mg
  • 50mg
  • 100mg

syrup/oral susp

  • 10mg/5mL

injectable solution

  • 25mg/mL
  • 50mg/mL

Anxiety

<6 years old: 50 mg/day PO divided q6hr

>6 years old: 50-100 mg/day PO divided q6hr

Pruritus

Management of pruritus due to chronic urticaria, contact dermatoses, and histamine-mediated pruritus

<6 years old: 50 mg/day PO divided q6hr

>6 years old: 50-100 mg/day PO divided q6hr

Preoperative Sedation

0.6 mg/kg PO  

0.5-1.1 mg/kg IM

Anxiety

Symptomatic relief of anxiety associated with psychoneurosis and as adjunct in organic disease states

50-100 mg PO divided q6hr or 50-100 mg IM divided q4-6hr

Continuation of therapy for >4 months has not been studied; reassess need for therapy periodically

Pruritus

25 mg PO/IM q6-8hr; increased to 25 mg q6-8hr

Nausea & Vomiting (Off-label)

25 mg IM

Dosing Modifications

Advanced age associated with reduced drug clearance and with greater risk of confusion, dry mouth, constipation, and other anticholinergic effects and toxicity; start at low end of dosage range, and observe closely

Next:

Interactions

Interaction Checker

and hydroxyzine

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (27)

              • amiodarone

                hydroxyzine increases toxicity of amiodarone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • artemether

                artemether and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • artemether/lumefantrine

                artemether/lumefantrine and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • bedaquiline

                bedaquiline and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • calcium/magnesium/potassium/sodium oxybates

                hydroxyzine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • ceritinib

                ceritinib and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • chloroquine

                chloroquine and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • citalopram

                hydroxyzine increases toxicity of citalopram by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • clozapine

                hydroxyzine increases toxicity of clozapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • crizotinib

                crizotinib and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • desflurane

                desflurane and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • droperidol

                hydroxyzine increases toxicity of droperidol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • eluxadoline

                hydroxyzine, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.

              • fexinidazole

                fexinidazole and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.

              • fluoxetine

                hydroxyzine increases toxicity of fluoxetine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • iloperidone

                hydroxyzine increases toxicity of iloperidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • isocarboxazid

                isocarboxazid increases effects of hydroxyzine by Other (see comment). Avoid or Use Alternate Drug. Comment: Isocarboxazid should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              • lefamulin

                lefamulin and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug.

              • metoclopramide intranasal

                hydroxyzine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

              • pitolisant

                hydroxyzine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.

              • procainamide

                hydroxyzine increases toxicity of procainamide by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • quetiapine

                hydroxyzine increases toxicity of quetiapine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • quinidine

                hydroxyzine increases toxicity of quinidine by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • sodium oxybate

                hydroxyzine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.

              • sotalol

                hydroxyzine increases toxicity of sotalol by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              • tranylcypromine

                tranylcypromine increases effects of hydroxyzine by Other (see comment). Avoid or Use Alternate Drug. Comment: Tranylcypromine should not be administered in combination with antihistamines because of potential additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines.

              • ziprasidone

                hydroxyzine increases toxicity of ziprasidone by QTc interval. Avoid or Use Alternate Drug. Increases risk of torsades de pointes.

              Monitor Closely (211)

              • albuterol

                hydroxyzine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                albuterol and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • alfentanil

                hydroxyzine and alfentanil both increase sedation. Use Caution/Monitor.

              • alfuzosin

                alfuzosin and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • alprazolam

                hydroxyzine and alprazolam both increase sedation. Use Caution/Monitor.

              • amifampridine

                hydroxyzine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.

              • amitriptyline

                hydroxyzine and amitriptyline both increase sedation. Use Caution/Monitor.

              • amobarbital

                hydroxyzine and amobarbital both increase sedation. Use Caution/Monitor.

              • amoxapine

                hydroxyzine and amoxapine both increase sedation. Use Caution/Monitor.

              • apomorphine

                hydroxyzine and apomorphine both increase sedation. Use Caution/Monitor.

                apomorphine and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • arformoterol

                hydroxyzine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                arformoterol and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • aripiprazole

                hydroxyzine and aripiprazole both increase sedation. Use Caution/Monitor.

                aripiprazole and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • armodafinil

                hydroxyzine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • atomoxetine

                atomoxetine and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • azelastine

                azelastine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • azithromycin

                hydroxyzine increases toxicity of azithromycin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • baclofen

                hydroxyzine and baclofen both increase sedation. Use Caution/Monitor.

              • belladonna and opium

                hydroxyzine and belladonna and opium both increase sedation. Use Caution/Monitor.

              • benperidol

                hydroxyzine and benperidol both increase sedation. Use Caution/Monitor.

              • benzphetamine

                hydroxyzine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • brexanolone

                brexanolone, hydroxyzine. Either increases toxicity of the other by sedation. Use Caution/Monitor.

              • brompheniramine

                brompheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • buprenorphine

                hydroxyzine and buprenorphine both increase sedation. Use Caution/Monitor.

              • buprenorphine buccal

                hydroxyzine and buprenorphine buccal both increase sedation. Use Caution/Monitor.

              • butabarbital

                hydroxyzine and butabarbital both increase sedation. Use Caution/Monitor.

              • butalbital

                hydroxyzine and butalbital both increase sedation. Use Caution/Monitor.

              • butorphanol

                hydroxyzine and butorphanol both increase sedation. Use Caution/Monitor.

              • caffeine

                hydroxyzine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • carbinoxamine

                carbinoxamine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • carisoprodol

                hydroxyzine and carisoprodol both increase sedation. Use Caution/Monitor.

              • chloral hydrate

                hydroxyzine and chloral hydrate both increase sedation. Use Caution/Monitor.

              • chlordiazepoxide

                hydroxyzine and chlordiazepoxide both increase sedation. Use Caution/Monitor.

              • chlorpheniramine

                chlorpheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • chlorpromazine

                hydroxyzine and chlorpromazine both increase sedation. Use Caution/Monitor.

                hydroxyzine increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • chlorzoxazone

                hydroxyzine and chlorzoxazone both increase sedation. Use Caution/Monitor.

              • cinnarizine

                cinnarizine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • clarithromycin

                hydroxyzine increases toxicity of clarithromycin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • clemastine

                clemastine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • clobazam

                hydroxyzine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).

              • clomipramine

                hydroxyzine and clomipramine both increase sedation. Use Caution/Monitor.

              • clonazepam

                hydroxyzine and clonazepam both increase sedation. Use Caution/Monitor.

              • clonidine

                clonidine, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects.

              • clorazepate

                hydroxyzine and clorazepate both increase sedation. Use Caution/Monitor.

              • clozapine

                hydroxyzine and clozapine both increase sedation. Use Caution/Monitor.

              • codeine

                hydroxyzine and codeine both increase sedation. Use Caution/Monitor.

              • cyclizine

                cyclizine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • cyclobenzaprine

                hydroxyzine and cyclobenzaprine both increase sedation. Use Caution/Monitor.

              • cyproheptadine

                cyproheptadine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • dantrolene

                hydroxyzine and dantrolene both increase sedation. Use Caution/Monitor.

              • dasatinib

                dasatinib and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • degarelix

                degarelix and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • desflurane

                desflurane and hydroxyzine both increase sedation. Use Caution/Monitor.

              • desipramine

                hydroxyzine and desipramine both increase sedation. Use Caution/Monitor.

              • deutetrabenazine

                hydroxyzine and deutetrabenazine both increase sedation. Use Caution/Monitor.

              • dexchlorpheniramine

                dexchlorpheniramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • dexfenfluramine

                hydroxyzine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dexmedetomidine

                hydroxyzine and dexmedetomidine both increase sedation. Use Caution/Monitor.

              • dexmethylphenidate

                hydroxyzine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextroamphetamine

                hydroxyzine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dextromoramide

                hydroxyzine and dextromoramide both increase sedation. Use Caution/Monitor.

              • diamorphine

                hydroxyzine and diamorphine both increase sedation. Use Caution/Monitor.

              • diazepam

                hydroxyzine and diazepam both increase sedation. Use Caution/Monitor.

              • diazepam intranasal

                diazepam intranasal, hydroxyzine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.

              • diethylpropion

                hydroxyzine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • difenoxin hcl

                hydroxyzine and difenoxin hcl both increase sedation. Use Caution/Monitor.

              • dimenhydrinate

                dimenhydrinate and hydroxyzine both increase sedation. Use Caution/Monitor.

              • diphenhydramine

                diphenhydramine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • diphenoxylate hcl

                hydroxyzine and diphenoxylate hcl both increase sedation. Use Caution/Monitor.

              • dipipanone

                hydroxyzine and dipipanone both increase sedation. Use Caution/Monitor.

              • dobutamine

                hydroxyzine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopamine

                hydroxyzine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dopexamine

                hydroxyzine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • dosulepin

                hydroxyzine and dosulepin both increase sedation. Use Caution/Monitor.

              • doxepin

                hydroxyzine and doxepin both increase sedation. Use Caution/Monitor.

              • doxylamine

                hydroxyzine and doxylamine both increase sedation. Use Caution/Monitor.

              • droperidol

                hydroxyzine and droperidol both increase sedation. Use Caution/Monitor.

              • ephedrine

                hydroxyzine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine

                hydroxyzine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • epinephrine racemic

                hydroxyzine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • erythromycin base

                hydroxyzine increases toxicity of erythromycin base by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • erythromycin ethylsuccinate

                hydroxyzine increases toxicity of erythromycin ethylsuccinate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • erythromycin lactobionate

                hydroxyzine increases toxicity of erythromycin lactobionate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • erythromycin stearate

                hydroxyzine increases toxicity of erythromycin stearate by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • esketamine intranasal

                esketamine intranasal, hydroxyzine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.

              • estazolam

                hydroxyzine and estazolam both increase sedation. Use Caution/Monitor.

              • ethanol

                hydroxyzine and ethanol both increase sedation. Use Caution/Monitor.

              • etomidate

                etomidate and hydroxyzine both increase sedation. Use Caution/Monitor.

              • fenfluramine

                hydroxyzine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fentanyl

                fentanyl, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl intranasal

                fentanyl intranasal, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transdermal

                fentanyl transdermal, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • fentanyl transmucosal

                fentanyl transmucosal, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.

              • flibanserin

                hydroxyzine and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.

              • fluphenazine

                hydroxyzine and fluphenazine both increase sedation. Use Caution/Monitor.

              • flurazepam

                hydroxyzine and flurazepam both increase sedation. Use Caution/Monitor.

              • formoterol

                hydroxyzine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • fostemsavir

                hydroxyzine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

              • gabapentin

                gabapentin, hydroxyzine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • gabapentin enacarbil

                gabapentin enacarbil, hydroxyzine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • glycopyrronium tosylate topical

                glycopyrronium tosylate topical, hydroxyzine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.

              • gotu kola

                gotu kola increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • haloperidol

                hydroxyzine and haloperidol both increase sedation. Use Caution/Monitor.

              • hawthorn

                hawthorn increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hops

                hops increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • hyaluronidase

                hydroxyzine decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.

              • hydromorphone

                hydroxyzine and hydromorphone both increase sedation. Use Caution/Monitor.

              • iloperidone

                hydroxyzine and iloperidone both increase sedation. Use Caution/Monitor.

              • imipramine

                hydroxyzine and imipramine both increase sedation. Use Caution/Monitor.

              • isoproterenol

                hydroxyzine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • kava

                kava increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • ketamine

                ketamine and hydroxyzine both increase sedation. Use Caution/Monitor.

              • ketotifen, ophthalmic

                hydroxyzine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.

              • lasmiditan

                lasmiditan, hydroxyzine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.

              • lemborexant

                lemborexant, hydroxyzine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.

              • levalbuterol

                hydroxyzine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • levorphanol

                hydroxyzine and levorphanol both increase sedation. Use Caution/Monitor.

              • lisdexamfetamine

                hydroxyzine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • lofepramine

                hydroxyzine and lofepramine both increase sedation. Use Caution/Monitor.

              • lofexidine

                hydroxyzine and lofexidine both increase sedation. Use Caution/Monitor.

              • loprazolam

                hydroxyzine and loprazolam both increase sedation. Use Caution/Monitor.

              • lorazepam

                hydroxyzine and lorazepam both increase sedation. Use Caution/Monitor.

              • lormetazepam

                hydroxyzine and lormetazepam both increase sedation. Use Caution/Monitor.

              • loxapine

                hydroxyzine and loxapine both increase sedation. Use Caution/Monitor.

              • loxapine inhaled

                hydroxyzine and loxapine inhaled both increase sedation. Use Caution/Monitor.

              • lurasidone

                lurasidone, hydroxyzine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.

              • maprotiline

                hydroxyzine and maprotiline both increase sedation. Use Caution/Monitor.

              • marijuana

                hydroxyzine and marijuana both increase sedation. Use Caution/Monitor.

              • melatonin

                hydroxyzine and melatonin both increase sedation. Use Caution/Monitor.

              • meperidine

                hydroxyzine and meperidine both increase sedation. Use Caution/Monitor.

              • meprobamate

                hydroxyzine and meprobamate both increase sedation. Use Caution/Monitor.

              • metaproterenol

                hydroxyzine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • metaxalone

                hydroxyzine and metaxalone both increase sedation. Use Caution/Monitor.

              • methadone

                hydroxyzine and methadone both increase sedation. Use Caution/Monitor.

                hydroxyzine increases toxicity of methadone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • methamphetamine

                hydroxyzine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • methocarbamol

                hydroxyzine and methocarbamol both increase sedation. Use Caution/Monitor.

              • methylenedioxymethamphetamine

                hydroxyzine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • midazolam

                hydroxyzine and midazolam both increase sedation. Use Caution/Monitor.

              • midazolam intranasal

                midazolam intranasal, hydroxyzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

              • midodrine

                hydroxyzine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • mirtazapine

                hydroxyzine and mirtazapine both increase sedation. Use Caution/Monitor.

              • modafinil

                hydroxyzine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • morphine

                hydroxyzine and morphine both increase sedation. Use Caution/Monitor.

              • motherwort

                hydroxyzine and motherwort both increase sedation. Use Caution/Monitor.

              • moxifloxacin

                hydroxyzine increases toxicity of moxifloxacin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • moxonidine

                hydroxyzine and moxonidine both increase sedation. Use Caution/Monitor.

              • nabilone

                hydroxyzine and nabilone both increase sedation. Use Caution/Monitor.

              • nalbuphine

                hydroxyzine and nalbuphine both increase sedation. Use Caution/Monitor.

              • norepinephrine

                hydroxyzine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • nortriptyline

                hydroxyzine and nortriptyline both increase sedation. Use Caution/Monitor.

              • olanzapine

                hydroxyzine and olanzapine both increase sedation. Use Caution/Monitor.

              • ondansetron

                hydroxyzine increases toxicity of ondansetron by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • opium tincture

                hydroxyzine and opium tincture both increase sedation. Use Caution/Monitor.

              • orphenadrine

                hydroxyzine and orphenadrine both increase sedation. Use Caution/Monitor.

              • osilodrostat

                osilodrostat and hydroxyzine both increase QTc interval. Use Caution/Monitor.

              • oxazepam

                hydroxyzine and oxazepam both increase sedation. Use Caution/Monitor.

              • oxycodone

                hydroxyzine and oxycodone both increase sedation. Use Caution/Monitor.

              • oxymorphone

                hydroxyzine and oxymorphone both increase sedation. Use Caution/Monitor.

              • paliperidone

                hydroxyzine and paliperidone both increase sedation. Use Caution/Monitor.

              • papaveretum

                hydroxyzine and papaveretum both increase sedation. Use Caution/Monitor.

              • papaverine

                hydroxyzine and papaverine both increase sedation. Use Caution/Monitor.

              • passion flower

                passion flower increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • pentamidine

                hydroxyzine increases toxicity of pentamidine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

              • pentazocine

                hydroxyzine and pentazocine both increase sedation. Use Caution/Monitor.

              • pentobarbital

                hydroxyzine and pentobarbital both increase sedation. Use Caution/Monitor.

              • perampanel

                perampanel and hydroxyzine both increase sedation. Use Caution/Monitor.

              • perphenazine

                hydroxyzine and perphenazine both increase sedation. Use Caution/Monitor.

              • phendimetrazine

                hydroxyzine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenelzine

                phenelzine increases effects of hydroxyzine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Coadministration of phenelzine and antihistamines may result in additive CNS depressant effects. MAO inhibitors also prolong and intensify anticholinergic effects of antihistamines. .

              • phenobarbital

                hydroxyzine and phenobarbital both increase sedation. Use Caution/Monitor.

              • phentermine

                hydroxyzine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine

                hydroxyzine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • phenylephrine PO

                hydroxyzine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

              • pholcodine

                hydroxyzine and pholcodine both increase sedation. Use Caution/Monitor.

              • pimozide

                hydroxyzine and pimozide both increase sedation. Use Caution/Monitor.

              • pirbuterol

                hydroxyzine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • pregabalin

                pregabalin, hydroxyzine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.

              • primidone

                hydroxyzine and primidone both increase sedation. Use Caution/Monitor.

              • prochlorperazine

                hydroxyzine and prochlorperazine both increase sedation. Use Caution/Monitor.

              • promethazine

                hydroxyzine and promethazine both increase sedation. Use Caution/Monitor.

              • propofol

                propofol and hydroxyzine both increase sedation. Use Caution/Monitor.

              • propylhexedrine

                hydroxyzine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • protriptyline

                hydroxyzine and protriptyline both increase sedation. Use Caution/Monitor.

              • quazepam

                hydroxyzine and quazepam both increase sedation. Use Caution/Monitor.

              • quetiapine

                hydroxyzine and quetiapine both increase sedation. Use Caution/Monitor.

              • ramelteon

                hydroxyzine and ramelteon both increase sedation. Use Caution/Monitor.

              • risperidone

                hydroxyzine and risperidone both increase sedation. Use Caution/Monitor.

              • salmeterol

                hydroxyzine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • scullcap

                hydroxyzine and scullcap both increase sedation. Use Caution/Monitor.

              • secobarbital

                hydroxyzine and secobarbital both increase sedation. Use Caution/Monitor.

              • sevoflurane

                sevoflurane and hydroxyzine both increase sedation. Use Caution/Monitor.

              • shepherd's purse

                hydroxyzine and shepherd's purse both increase sedation. Use Caution/Monitor.

              • stiripentol

                stiripentol, hydroxyzine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

              • sufentanil

                hydroxyzine and sufentanil both increase sedation. Use Caution/Monitor.

              • tapentadol

                hydroxyzine and tapentadol both increase sedation. Use Caution/Monitor.

              • temazepam

                hydroxyzine and temazepam both increase sedation. Use Caution/Monitor.

              • terbutaline

                hydroxyzine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • thioridazine

                hydroxyzine and thioridazine both increase sedation. Use Caution/Monitor.

              • thiothixene

                hydroxyzine and thiothixene both increase sedation. Use Caution/Monitor.

              • topiramate

                hydroxyzine and topiramate both increase sedation. Modify Therapy/Monitor Closely.

              • tramadol

                hydroxyzine and tramadol both increase sedation. Use Caution/Monitor.

              • trazodone

                hydroxyzine and trazodone both increase sedation. Use Caution/Monitor.

              • triazolam

                hydroxyzine and triazolam both increase sedation. Use Caution/Monitor.

              • triclofos

                hydroxyzine and triclofos both increase sedation. Use Caution/Monitor.

              • trifluoperazine

                hydroxyzine and trifluoperazine both increase sedation. Use Caution/Monitor.

              • trimipramine

                hydroxyzine and trimipramine both increase sedation. Use Caution/Monitor.

              • triprolidine

                hydroxyzine and triprolidine both increase sedation. Use Caution/Monitor.

              • valerian

                valerian increases effects of hydroxyzine by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.

              • xylometazoline

                hydroxyzine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • yohimbine

                hydroxyzine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.

              • ziconotide

                hydroxyzine and ziconotide both increase sedation. Use Caution/Monitor.

              • ziprasidone

                hydroxyzine and ziprasidone both increase sedation. Use Caution/Monitor.

              • zotepine

                hydroxyzine and zotepine both increase sedation. Use Caution/Monitor.

              Minor (6)

              • ashwagandha

                ashwagandha increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              • brimonidine

                brimonidine increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.

              • eucalyptus

                hydroxyzine and eucalyptus both increase sedation. Minor/Significance Unknown.

              • nettle

                nettle increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.

              • sage

                hydroxyzine and sage both increase sedation. Minor/Significance Unknown.

              • Siberian ginseng

                Siberian ginseng increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.

              Previous
              Next:

              Adverse Effects

              Frequency Not Defined

              Anticholinergic: Dry mouth

              Central nervous system: Drowsiness (usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose), involuntary motor activity (tremor, convulsions) usually with doses considerably higher than those recommended

              Clinically significant respiratory depression has not been reported at recommended doses

              Postmarketing Reports

              Body as a whole: Allergic reaction

              Nervous system: Headache

              Psychiatric: Hallucination

              Skin and appendages: Pruritus, rash, urticaria, fixed drug eruptions

              Previous
              Next:

              Warnings

              Contraindications

              Documented hypersensitivity or related product including cetirizine and levocetirizine and components of the formulation

              Prolonged QT interval

              SC, intra-arterial, or IV administration

              Cautions

              Nursing mothers

              May cause CNS depression resulting in drowsiness; avoid driving or operating dangerous machinery

              May cause oversedation and confusion in elderly patients; start on lower doses and monitor closely; avoid use

              IM only for parenteral use; switch to PO ASAP

              Use caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or respiratory disease (asthma or COPD)

              Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema; if signs or symptoms suggest AGEP, do not resume use of hydroxyzine and consider alternative therapy; avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to risk of cross-sensitivity

              Drug interaction interview

              • Caution recommended during concomitant use of drugs known to prolong QT interval including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol)
              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy category: Considered to be contraindicated in early (1st trimester) pregnancy until more human pregnancy data available; limited experience in human pregnancy, either for drug itself or drugs in same class or with similar mechanisms of action, including 1st trimester, current limited data suggests that the drug does not represent a significant risk of developmental toxicity including growth restriction, structural anomalies, functional/behavioral deficits, or death at any time in pregnancy

              Lactation: Excretion in milk unknown; use with caution

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              H1-receptor antagonist with low to moderate antihistaminic properties; inhibits respiratory, vascular, and GI smooth-muscle constriction

              Moderate to high anticholinergic and antiemetic properties

              Absorption

              Onset: 15-30 min (PO)

              Duration: Sedation, 4-6 hr; antipruritic, 1-12 hr; histamine-induced wheal and flare, 2-36 hr

              Peak serum time: 1-2 hr

              Distribution

              Vd: 16 L/kg (adults); 23 L/kg (elderly)

              Metabolism

              Metabolized by liver

              Elimination

              Half-life: 20 hr (adults); 29 hr (elderly); 37 hr (hepatic dysfunction)

              Excretion: Urine

              Previous
              Next:

              Administration

              IM Incompatibilities

              Additive: Aminophylline, amobarbital, chloramphenicol, ketorolac, penicillin G sodium/potassium, pentobarbital, phenobarbital

              Syringe: Aminophylline, dimenhydrinate, haloperidol, heparin, ketorolac, penicillin, pentobarbital, phenytoin, ranitidine, vitamin B complex with C

              IM Compatibilities

              Additive (partial list): Cisplatin, cyclophosphamide, cytarabine, dimenhydrinate, etoposide, lidocaine, methotrexate, nafcillin

              Syringe (partial list): Atropine, buprenorphine, cimetidine, diphenhydramine, fentanyl, glycopyrrolate, lidocaine, meperidine, midazolam, morphine, promethazine, scopolamine, sufentanil

              Previous
              Next:

              Images

              BRAND FORM. UNIT PRICE PILL IMAGE
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              10 mg/5 mL solution
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl oral
              -
              25 mg tablet
              hydroxyzine HCl oral
              -
              10 mg/5 mL solution
              hydroxyzine HCl oral
              -
              10 mg/5 mL solution
              hydroxyzine HCl oral
              -
              10 mg tablet
              hydroxyzine HCl oral
              -
              50 mg tablet
              hydroxyzine HCl intramuscular
              -
              50 mg/mL vial
              hydroxyzine HCl intramuscular
              -
              50 mg/mL vial
              hydroxyzine HCl intramuscular
              -
              50 mg/mL vial
              hydroxyzine HCl intramuscular
              -
              25 mg/mL vial

              Copyright © 2010 First DataBank, Inc.

              Previous
              Next:

              Patient Handout

              Select a drug:
              Patient Education
              hydroxyzine HCl oral

              HYDROXYZINE HYDROCHLORIDE - ORAL

              (hye-DROX-i-zeen HYE-droe-KLOR-ide)

              COMMON BRAND NAME(S): Atarax

              USES: Hydroxyzine is used to treat itching caused by allergies. It is an antihistamine and works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Hydroxyzine may also be used short-term to treat anxiety or to help you feel sleepy/relaxed before and after surgery.

              HOW TO USE: Take this medication by mouth with or without food as directed by your doctor, usually three or four times daily. If you are using the liquid form of this medication, carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.The dosage is based on your age, medical condition, and response to treatment. In children, the dosage may also be based on weight. Do not increase your dose or take this medication more often than directed.Tell your doctor if your condition does not improve or if it worsens.

              SIDE EFFECTS: Drowsiness, dizziness, blurred vision, constipation, or dry mouth may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.To relieve dry mouth, suck (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as restlessness, confusion, hallucinations), shaking (tremor), difficulty urinating.Get medical help right away if you have any very serious side effects, including: seizures, fast/irregular heartbeat, severe dizziness, fainting.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking hydroxyzine, tell your doctor or pharmacist if you are allergic to it; or to cetirizine; or to levocetirizine; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (such as emphysema, asthma), high pressure in the eye (glaucoma), high blood pressure, kidney problems, liver problems, seizures, stomach/intestine problems (such as ulcer, blockage), overactive thyroid (hyperthyroidism), difficulty urinating (for example, due to enlarged prostate).Hydroxyzine may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before taking hydroxyzine, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about taking hydroxyzine safely.This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Liquid products may contain sugar and/or alcohol. Caution is advised if you have diabetes, liver disease, or any other condition that requires you to limit/avoid these substances in your diet. Ask your doctor or pharmacist about using this product safely.Children may be more sensitive to the side effects of this drug. This drug can often cause excitement in young children instead of drowsiness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, constipation, trouble urinating or QT prolongation (see above). Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or other antihistamines (such as diphenhydramine, promethazine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.Do not use with any other antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray) because increased side effects may occur.Hydroxyzine is very similar to cetirizine and levocetirizine. Do not use these medications while using hydroxyzine.This medication may interfere with certain laboratory tests (including allergy skin testing, urine corticosteroids level), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness, seizures. In children, mental/mood changes (such as restlessness, irritability) may occur before drowsiness.

              NOTES: Do not share this medication with others.

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Do not freeze liquid forms of this medication. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.